In two studies, the use of ESCAT matching and ESMO recommendations for germline assessment lead to effective targeted treatment

Early activity and manageable safety were demonstrated in two phase I trials with innovative agents 

Preclinical findings show antitumour activity of triple KRAS inhibition in mouse models, but it will take years of rigorous research to assess its clinical efficacy in oncology patients

Phase I–II studies showcase the clinical potential of novel ADCs with enhanced targeting and/or payload strategies

Studies underline that a tumour-agnostic approach may help improve treatment options

A triple combination investigated in a phase I trial adds to the growing therapeutic options directed at this emerging target 

The combination of lenvatinib plus everolimus improved progression-free survival in the LenCabo trial, but toxicity must be carefully assessed

In the evERA BC trial, giredestrant plus everolimus led to a prolonged progression-free survival

In early phase studies, IAG933 and VT3989 led to encouraging disease control rates with manageable toxicity

Positive initial overall survival data were, however, attenuated and may not be clinically meaningful in a longer-term analysis